Bivalirudin versus heparin in patients undergoing percutaneous coronary intervention in acute coronary syndromes
Comparative review published in Critical Pathways in Cardiology (2025)
Abstract
INTRODUCTION: Data on outcomes between unfractionated heparin and bivalirudin anticoagulation during percutaneous coronary intervention (PCI) in acute coronary syndromes remain inconclusive. We aimed to systematically analyze PCI outcomes by comparing unfractionated heparin and bivalirudin. METHODS: We systematically searched Ovid MEDLINE, Ovid Embase, Ovid Cochrane Database of Systematic Reviews, Scopus, and Web of Science from database inception in 1966 through January 2024 for studies evaluating PCI outcomes comparing unfractionated heparin and bivalirudin. Two investigators independently reviewed the data. Conflicts were resolved through consensus. Random-effects meta-analyses were used. RESULTS: A total of 10 prospective trials were identified that enrolled 42,253 individuals who presented with an acute coronary syndrome. Our analysis found that heparin when compared to bivalirudin was associated with an increased risk of trial-based definition of major bleeding [relative risk (RR): 1.68, 95% confidence interval (CI): 1.29-2.20], nonaccess site complications (RR: 4.6, 95% CI: 1.75-12.09), thrombolysis in myocardial infarction major bleeding (RR: 1.70, 95% CI: 1.20-2.41), major bleeding risks (RR: 1.87, 95% CI: 1.49-2.36), cardiovascular disease death (RR: 1.26, 95% CI: 1.02-1.57), and thrombocytopenia (RR: 1.67, 95% CI: 1.07-2.62). There were no statistically significant differences between heparin and bivalirudin for all-cause mortality, major adverse cardiovascular event, stroke, reinfarction, target vessel revascularization, and acute or stent thrombosis. CONCLUSIONS: The present meta-analysis demonstrates bivalirudin reduces major bleeding when used for anticoagulation during PCI in patients with acute coronary syndromes and is not associated with an increased risk of stent thrombosis or major adverse cardiovascular event.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Modern review comparing bivalirudin vs heparin in ACS PCI through the BRIGHT-4 era, with practical algorithm for selection by bleeding risk and dosing strategy.
Why This Matters for Hirudotherapy
This systematic review and meta-analysis compared unfractionated heparin with bivalirudin for anticoagulation during percutaneous coronary intervention in acute coronary syndromes, pooling data from 10 prospective trials enrolling 42,253 patients. Heparin was associated with significantly higher risks of major bleeding, nonaccess site complications, cardiovascular death, and thrombocytopenia compared to bivalirudin, while no significant differences were found for all-cause mortality, stent thrombosis, or major adverse cardiovascular events. The abstract does not discuss leeches, hirudin origin, or hirudotherapy, so no defensible link to ASH's domain can be established from this article alone. The findings pertain to pharmaceutical anticoagulation in interventional cardiology and are not directly applicable to traditional leech therapy.
Citation
Bivalirudin versus heparin in patients undergoing percutaneous coronary intervention in acute coronary syndromes.
Krittanawong C et al. · Critical pathways in cardiology, 2025
Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026